← Back to guidelines
Infectious Disease1 paper

Tuberculosis of cerebral meninges

Last edited: 4/10/2026

Overview

Tuberculous meningitis (TBM) is the most severe manifestation of tuberculosis, resulting in death or permanent disability in approximately half of all affected patients 1. Diagnosis is frequently delayed due to the lack of a single rapid and accurate diagnostic test, necessitating the use of multi-parameter predictive models and specialized cerebrospinal fluid (CSF) assays 2.

Diagnosis

  • Clinical Prediction Models: Diagnostic accuracy is improved by integrating variables including CSF glucose, blood glucose, CSF white cell count and differential, HIV status, fever, and cryptococcal antigen 2.
  • CSF Adenosine Deaminase (ADA): ADA measurement is a highly effective diagnostic tool (AUC 0.94) for both adults and children; performance is optimal using cutoffs ≤10 U/L 4.
  • Interferon-gamma (IFN-γ) Assays: Unstimulated CSF IFN-γ provides excellent diagnostic accuracy (AUC 0.95), while CSF IGRA (AUC 0.93) and blood IGRA (AUC 0.86) also serve as useful diagnostic adjuncts 5.
  • Radiological Indicators: The presence of hydrocephalus and meningeal enhancement on imaging are significant markers for TBM and are associated with increased risk of complications 3.
  • Case Definitions: Clinical research typically categorizes cases as "definite" or "probable" TBM based on standardized case definitions to account for diagnostic uncertainty 2.
  • Management

  • Multidisciplinary Care: Optimal management requires a structured approach addressing anti-tuberculosis chemotherapy, adjunctive anti-inflammatory therapy, and neurocritical or neurosurgical intervention 1.
  • Cerebrovascular Monitoring: Patients must be screened for stroke risk, as cerebrovascular complications occur in 15% to 57% of TBM cases 3.
  • Risk Factor Modification: Management should address modifiable risk factors for complications, including hypertension and smoking, which are associated with increased stroke risk in TBM 3.
  • Special Populations

  • Pediatrics: CSF ADA testing demonstrates high diagnostic efficacy in children (AUC 0.96), comparable to its performance in adult populations 4.
  • HIV-Positive Patients: HIV status is a critical variable in TBM diagnostic algorithms and must be considered when interpreting clinical prediction models 2.
  • Patients with Comorbidities: Individuals with diabetes mellitus, hypertension, or ischemic heart disease are at significantly higher risk for secondary cerebrovascular complications 3.
  • Key Recommendations

  • Utilize CSF adenosine deaminase (ADA) as a rapid diagnostic test for TBM in adults and children, ideally utilizing a cutoff of 10 U/L to maximize accuracy (Evidence: Strong) 4.
  • Employ unstimulated CSF IFN-γ testing where available, as it offers superior diagnostic accuracy over stimulated IGRA methods for differentiating TBM from other conditions (Evidence: Strong) 5.
  • Apply validated clinical prediction models or mobile diagnostic applications that integrate CSF biochemistry, cellular analysis, and clinical markers to mitigate delays in treatment (Evidence: Strong) 2.
  • Perform early screening for stroke risk in patients presenting with focal deficits, cranial nerve palsies, or significant meningeal enhancement on imaging (Evidence: Strong) 3.
  • Follow international consortium guidance for the standardized administration of anti-tuberculosis chemotherapy and adjunctive anti-inflammatory agents (Evidence: Expert opinion) 1.
  • References

    1 Donovan J, Cresswell FV, Tucker EW, Davis AG, Rohlwink UK, Huynh J et al.. A clinical practice guideline for tuberculous meningitis. The Lancet. Infectious diseases 2026. link00364-0) 2 Stadelman-Behar AM, Tiffin N, Ellis J, Creswell FV, Ssebambulidde K, Nuwagira E et al.. Diagnostic Prediction Model for Tuberculous Meningitis: An Individual Participant Data Meta-Analysis. The American journal of tropical medicine and hygiene 2024. link 3 Tomidy J, Satriadinatha GBY, Liwang FK, Maharani K, Imran D, Estiasari R. Prognostic identifier of cerebrovascular complications in tuberculous meningitis: Meta-analysis. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2023. link 4 Ye Q, Yan W. Adenosine deaminase from the cerebrospinal fluid for the diagnosis of tuberculous meningitis: A meta-analysis. Tropical medicine & international health : TM & IH 2023. link 5 Shi F, Qiu X, Yu M, Huang Y. Tuberculosis-specific antigen stimulated and unstimulated interferon-γ for tuberculous meningitis diagnosis: A systematic review and meta-analysis. PloS one 2022. link

    Original source

    1. [1]
      A clinical practice guideline for tuberculous meningitis.Donovan J, Cresswell FV, Tucker EW, Davis AG, Rohlwink UK, Huynh J et al. The Lancet. Infectious diseases (2026)
    2. [2]
      Diagnostic Prediction Model for Tuberculous Meningitis: An Individual Participant Data Meta-Analysis.Stadelman-Behar AM, Tiffin N, Ellis J, Creswell FV, Ssebambulidde K, Nuwagira E et al. The American journal of tropical medicine and hygiene (2024)
    3. [3]
      Prognostic identifier of cerebrovascular complications in tuberculous meningitis: Meta-analysis.Tomidy J, Satriadinatha GBY, Liwang FK, Maharani K, Imran D, Estiasari R Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2023)
    4. [4]
      Adenosine deaminase from the cerebrospinal fluid for the diagnosis of tuberculous meningitis: A meta-analysis.Ye Q, Yan W Tropical medicine & international health : TM & IH (2023)
    5. [5]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG